PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-4889

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations ; volume:9 ; number:2 ; day:19 ; month:1 ; year:2018 ; pages:1-15 ; date:2.2018
Cell death & disease ; 9, Heft 2 (19.1.2018), 1-15, 2.2018

Keyword: Krebs
Onkologie

Creator: di Blasio, Laura

Contributor: Puliafito, Alberto
Gagliardi, Paolo Armando
Comunanza, Valentina
Somale, Desiana
Chiaverina, Giulia
Bussolino, Federico
Primo, Luca
SpringerLink (Online service)

DOI: 10.1038/s41419-017-0064-x

URN: urn:nbn:de:1111-201804138591

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

di Blasio, Laura
Puliafito, Alberto
Gagliardi, Paolo Armando
Comunanza, Valentina
Somale, Desiana
Chiaverina, Giulia
Bussolino, Federico
Primo, Luca
SpringerLink (Online service)

Other Objects (12)

PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

PIK3CA-mutations in breast cancer

Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

PIK3CA mutations in endocrine-resistant breast cancer

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

PIK3CA-mutations in breast cancer

Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

PIK3CA mutations in endocrine-resistant breast cancer

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

PIK3CA-mutations in breast cancer

Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

PIK3CA mutations in endocrine-resistant breast cancer

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

PIK3CA-mutations in breast cancer

Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

PIK3CA mutations in endocrine-resistant breast cancer

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

PIK3CA-mutations in breast cancer

Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

PIK3CA mutations in endocrine-resistant breast cancer

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

PIK3CA-mutations in breast cancer

Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

PIK3CA mutations in endocrine-resistant breast cancer

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Related objects

Reset password